Loading...
Market
How will Novartis' stock performance compare to its competitors by the end of Q1 2025?
3
Resolution / Starting Odds
Novartis outperforms competitors • 25%
Novartis performs equally as competitors • 25%
Novartis underperforms competitors • 25%
Stock performance is inconclusive • 25%
Stock performance data from financial platforms like Bloomberg or Yahoo Finance
Story
FDA Approves Novartis' Kisqali (Ribociclib) for Early Breast Cancer
Sep 17, 2024, 08:50 PM
The FDA has approved Novartis' drug Kisqali (ribociclib) for the treatment of adults with stage 2 and 3 hormone receptor-positive, HER2-negative breast cancer at high risk of recurrence. This expanded approval, based on the efficacy and safety results of the NATALEE trial, will allow tens of thousands of women access to a drug that could help prevent their cancer from returning. The approval also includes the use of ribociclib in combination with an aromatase inhibitor. This development is expected to significantly expand the market for Kisqali, giving it a competitive edge over rival treatments.
View original story
Similar markets
Outperform • 25%
Underperform • 25%
Match performance • 25%
Significantly underperform • 25%
Outperform significantly • 25%
Outperform slightly • 25%
Underperform • 25%
Match performance • 25%
Outperforms sector • 25%
Matches sector performance • 25%
Underperforms sector • 25%
Significant volatility • 25%
Outperforms all • 25%
Outperforms some • 25%
Matches performance • 25%
Underperforms all • 25%
Higher than competitors • 25%
On par with competitors • 25%
Lower than competitors • 25%
Significantly lower than competitors • 25%
Yes • 50%
No • 50%
Outperform • 25%
Match • 25%
Underperform • 25%
Significantly underperform • 25%
Outperforms all major competitors • 25%
Performs similarly to major competitors • 25%
Underperforms compared to some competitors • 25%
Underperforms all major competitors • 25%
Roche outperforms Merck • 25%
Merck outperforms Roche • 25%
Both perform similarly • 25%
Both underperform the market • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
No change or decrease • 25%
Decrease by more than 10% • 25%
Novo Nordisk outperforms • 25%
Eli Lilly outperforms • 25%
Both perform equally • 25%
Both underperform • 25%
